Royalty Pharma (RPRX) Capital Expenditures (2019 - 2026)

Royalty Pharma has reported Capital Expenditures for 8 years, with the latest figure at $452.4 million in Q1 2026.

• Quarterly Capital Expenditures rose 42697.16% year-over-year to $452.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 billion (down 11.22% YoY) and the FY2025 annual result came in at $1.7 billion, down 32.25% from the prior year.
• Capital Expenditures eased to $452.4 million in Q1 2026 per RPRX's latest filing, from $733.7 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $1.3 billion in Q3 2022 and troughed at $85000.0 in Q1 2022.
• A 5-year average of $500.8 million and a median of $452.4 million in 2026 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures plunged 99.98% in 2022, then jumped 707788.24% in 2023.
• Over 5 years, Capital Expenditures stood at $250.2 million in 2022, then soared by 300.51% to $1.0 billion in 2023, then slumped by 50.47% to $496.4 million in 2024, then soared by 47.8% to $733.7 million in 2025, then sank by 38.34% to $452.4 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $452.4 million, $733.7 million, and $961.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.